Literature DB >> 8464344

Anticonvulsant effects of intracerebroventricularly administered norepinephrine are potentiated in the presence of monoamine oxidase inhibition in severe seizure genetically epilepsy-prone rats (GEPR-9s).

P K Mishra1, E H Kahle, A F Bettendorf, J W Dailey, P C Jobe.   

Abstract

Pharmacological and neurochemical evidence indicates that brain noradrenergic systems play an important role in the determination of audiogenic seizure severity in genetically epilepsy-prone rats (GEPRs). In earlier studies, intracerebroventricular (ICV) injections of norepinephrine suppressed convulsions in a now extinct moderate seizure GEPR colony. Also, ICV noradrenergic agonists are known to produce dose-related anticonvulsant effects in the extant moderate seizure GEPRs (GEPR-3s). The present experiments were undertaken to determine whether ICV norepinephrine also suppresses audiogenic seizures in the extant GEPR-3s and in the severe seizure genetically epilepsy-prone rats (GEPR-9s). Injections of norepinephrine or vehicle were made into the lateral ventricle through implanted guides. GEPR-9s were pretreated systemically either with the monoamine oxidase inhibitor pargyline or with saline. GEPR-3s received no pretreatment. In pargyline pretreated GEPR-9s, seizure severity fell and the fraction of animals exhibiting an anticonvulsant response increased progressively as the dose of norepinephrine was increased. In saline pretreated GEPR-9s, the anticonvulsant dose response curve for norepinephrine was shifted to a higher dose range. Accordingly, the anticonvulsant dose50 for norepinephrine was significantly greater in saline pretreated GEPR-9s than in pargyline pretreated animals. Moreover, the dose required to produce the anticonvulsant effect in GEPR-9s was approximately 10 fold greater than in the earlier studies in the extinct moderate seizure GEPRs. Also, the current experiment with extent GEPR-3s, showed that ICV norepinephrine was anticonvulsant in the same dose that was effective in the extinct colony of moderate seizure GEPRs. In general terms, these observations provide additional evidence that noradrenergic influences are anticonvulsant in the GEPR. The neurobiological factors responsible for reduced responsiveness of the GEPR-9 are presently unknown.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8464344     DOI: 10.1016/0024-3205(93)90067-d

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

Review 1.  The role of the central noradrenergic system in behavioral inhibition.

Authors:  Eric A Stone; Yan Lin; Yasmeen Sarfraz; David Quartermain
Journal:  Brain Res Rev       Date:  2011-03-05

Review 2.  Selecting an antidepressant for use in a patient with epilepsy. Safety considerations.

Authors:  S Curran; K de Pauw
Journal:  Drug Saf       Date:  1998-02       Impact factor: 5.606

3.  Effect of monoamine reuptake inhibition and α1 blockade on respiratory arrest and death following electroshock-induced seizures in mice.

Authors:  Stephen W Kruse; Kyle G Dayton; Benton S Purnell; Jared I Rosner; Gordon F Buchanan
Journal:  Epilepsia       Date:  2019-02-05       Impact factor: 5.864

4.  Mechanisms of Psychiatric Comorbidities in Epilepsy.

Authors:  Jamie Maguire
Journal:  Curr Top Behav Neurosci       Date:  2022
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.